Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05518487 Active, not recruiting - COVID-19 Clinical Trials

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study

CPAT-SG
Start date: February 20, 2023
Phase: Phase 2
Study type: Interventional

An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have =<2500 U/mL SARS-CoV-2 S antibody concentration using the Roche Elecsys(R) anti-RBD assay. Up to 80 participants will be enrolled in this study. Eligible participants will receive a dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine candidate.. The primary objective is to determine whether a booster dose of the Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine will elicit an increased SARS-CoV-2 antibody response in participants who have failed to maintain an antibody titer >2500 U/mL (using the Roche Elecsys(R) anti-RBD assay) to 2 or more doses of mRNA based COVID-19 vaccine

NCT ID: NCT05518474 Terminated - COVID-19 Clinical Trials

Self-proning and Repositioning in COVID-19 Outpatients at Risk of Complicated Illness

Start date: October 15, 2021
Phase: N/A
Study type: Interventional

The rapid development of safe and effective COVID-19 treatment is a global health priority. Numerous studies evaluating therapies for this disease are currently underway, but the majority of these are in hospitalized patients with severe illness. Consequently, there is an urgent need to identify therapies that prevent mild COVID-19 cases in the community from becoming more severe. "Proning" or lying face down in bed has been shown to improve breathing and oxygen levels in COVID-19 patients, reducing the need for breathing tubes and ventilators and increasing survival. The current study will investigate whether proning and repositioning (lying on one's side or sitting up) can prevent mild cases of COVID-19 from becoming more severe resulting in fewer hospitalizations and death. A randomized controlled trial will be used to reduce the risk of bias when testing this intervention. Unvaccinated or partially vaccinated adult patients with a positive COVID-19 test willing to participate and well enough to be treated outside the hospital will be randomly assigned to one of two groups: a home-proning intervention group with instructions and daily reminders to prone and reposition during the day and at night, and a standard care group. Our goal is to assess whether home-proning/repositioning leads to fewer hospitalizations and death when compared with standard care. We'll also compare recovery time, use of antibiotics and follow up emergency department visits between these two groups. The current pilot study will assess the feasibility of a larger investigation or "main trial", meaning it will be small scale test of methods and procedures to be used on a larger scale.

NCT ID: NCT05518461 Completed - COVID-19 Clinical Trials

Smartphone Intervention for Overdose and COVID-19

Start date: December 19, 2022
Phase: N/A
Study type: Interventional

This study will examine if the use of a smartphone application called Thrive4Life Connect can help people who use drugs lower their risk of overdose and learn more about COVID-19 vaccines. 60 participants will be enrolled and can expect to be on study for up to 6 months.

NCT ID: NCT05517941 Completed - Clinical trials for Corona Virus Infection

Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient

COVID19
Start date: September 15, 2022
Phase: N/A
Study type: Interventional

this study will be conducted to investigate the effect of Active Cycle Breathing Technique and incentive spirometer on COVID19 patient

NCT ID: NCT05517642 Completed - COVID-19 Clinical Trials

IH Convidecia as Second Booster Dose Against Breakthrough Infections

Start date: September 20, 2022
Phase: Phase 3
Study type: Interventional

This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent breakthrough infections among people with a sub-optimal immune response to the first booster dose. These subjects will be randomized in a ratio of 1:1 to receive a second booster dose of IH Convidecia vaccine (treatment arm), or a second booster dose of mRNA vaccine BNT162b2 (Pfizer).

NCT ID: NCT05517629 Completed - COVID-19 Clinical Trials

Face Mask Habits and COVID-19 Among University Students in Cairo

Start date: April 20, 2021
Phase:
Study type: Observational

The World Health Organization officially declared the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a public health emergency. The virus can remain viable in aerosol form for approximately three hours before being inhaled. Face masks have become an essential component of the ensuing fight against coronavirus disease 2019 (COVID-19).Therefore, a multicenter cross-sectional study was conducted during the pandemic to investigate university students' face mask habits in Greater Cairo, Egypt.

NCT ID: NCT05517148 Completed - Stress Clinical Trials

Effects of an Immersive Virtual Reality Intervention Combined With Mindfulness-based Stress Reduction

Start date: September 25, 2022
Phase: N/A
Study type: Interventional

Mindfulness-based stress reduction (MBSR), a widely used method to improve mental state and sleep quality, was developed by Kabat-Zinn in 1970. The meditation of MBSR is effective in regulating patients' emotions, leading to reduced stress, pain, and psychological symptoms. Studies have demonstrated that MBSR has a positive impact on multiple psychological and physical symptoms in a variety of cancers. On this basis, investigators found that VR treatment can also help patients relax, and it has been widely used in cancer symptom relief in recent years. VR treatment involves using headset devices that fully restrict the vision field to content displayed inside the headset screen; As a treatment modality, VR provides a unique environment comprising 3D visually immersive experiences that are enriched with stereo sounds and elements such as rich colors and scenic environments that enhance elicitation of desired states of arousal and affect. Within the therapeutic context, VR may be flexibly designed and tailored to address the needs of specific conditions (eg, anxiety, depression, pain) auditory perception is not fully restricted, though the corresponding device-delivered auditory content commands attention.

NCT ID: NCT05516836 Recruiting - Pain Clinical Trials

Addressing Post-COVID-19 Musculoskeletal Symptoms

Start date: March 20, 2023
Phase: N/A
Study type: Interventional

The purpose of the study will be to evaluate the effect of a rehabilitation program on the improvement of patients with post-COVID-19 musculoskeletal symptoms, as well as to quantify the impact of telemedicine that evaluates the evolution of pain, functionality, and quality of life.

NCT ID: NCT05516550 Not yet recruiting - Clinical trials for SARS-CoV-2 Infection

Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19

Start date: August 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The innovative drug Treamid is planned for use in the treatment of patients with persistent lung damage and reduced exercise tolerance exertion after COVID-19 pneumonia in a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III clinical study to assess the efficacy and safety of Treamid during a 28-day treatment. The primary objective of the study is to prove that in the Treamid group, the proportion of patients achieving clinically significant load tolerance is statistically significantly higher than in the placebo group. The secondary objective of the study is to evaluate the safety of Treamid and achievement of clinically significant improvements in indicators for various questionnaires and spirometry data.

NCT ID: NCT05515276 Completed - Allergy Clinical Trials

The COVID-19 Pandemic Process Increase Latex Glove Use and Latex Allergy Complaints in Hospital Nurses? Survey Study

COVID19LATEX
Start date: June 1, 2021
Phase:
Study type: Observational [Patient Registry]

Background: Global guidelines recommend the use of personal protective equipment due to the high risk of contagiousness of COVID-19 disease. The increase in COVİD-19 patients in the last two years has increased the rate of use of latex gloves in nurses. It is not known how the increase in the use of latex gloves affects the complaints of latex allergy in nurses. Aim: The aim of this study is to determine the rates of latex glove use and allergic complaints related to the use of latex gloves during the COVID-19 pandemic in hospital nurses.